PHR1851

奥美沙坦酯

Pharmaceutical Secondary Standard; Certified Reference Material

• 同義詞: Olmesartan medoxomil
• 經驗公式（希爾表示法）: C₂₉H₃₀N₆O₆
• CAS號碼: 144689-63-4
• 分子量：: 558.59
• MDL號碼: MFCD00944911
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: certified reference material; pharmaceutical secondary standard
• 品質等級: 300
• agency: traceable to BP 1173; traceable to Ph. Eur. Y0001405; traceable to USP 1478367
• API 家族: olmesartan
• CofA: current certificate can be downloaded
• 包裝: pkg of 200 mg
• 應用: pharmaceutical
• 格式: neat
• 儲存溫度: -10 to -25°C
• SMILES 字串: CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5
• InChI: 1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
• InChI 密鑰: UQGKUQLKSCSZGY-UHFFFAOYSA-N
• 基因資訊: human ... AGTR1(185)

描述

一般說明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Olmesartan Medoxomil is an AT₁ subtype angiotensin-II receptor antagonist used in the management of hypertension. It prevents angiotensin II from binding to the AT₁ receptors, thereby decreasing vasoconstriction.

應用

Theis pharmaceutical secondary standard can also be used as follows:

• Development and validation of an isocratic ultra-high performance liquid chromatography (UHPLC) based stability indicating method to determine olmesartan medoxomil and amlodipine besylate in combined tablet dosage forms
• Simultaneous determination of Olmesartan medoxomil and chlorthalidone by reversed phase-high performance liquid chromatography (RP-HPLC) in tablets
• Quantification of olmesartan medoxomil and its degradation products in bulk drugs and pharmaceutical formulations by using a systematic quality by design (QbD)-based reverse-phase liquid chromatography method
• Reversed phase-high performance liquid chromatographic (RP-HPLC) analysis of olmesartan medoxomil and hydrochlorothiazide in their combined tablet dosage form
• Determination of olmesartan medoxomil and amlodipine besylate in their combined tablet dosage form by absorption subtraction method, ratio subtraction with extended ratio subtraction method, dual wavelength technique, and second order derivative spectrophotometry

分析報告

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

腳註

To see an example of a Certificate of Analysis for this material enter LRAC2529 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H302 + H312 + H332
• 防範說明: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• 危險分類: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable